INDUCTION OF OPSONIZING ANTIBODIES AFTER INJECTION OF RECOMBINANT PLASMODIUM-FALCIPARUM VACCINE CANDIDATE ANTIGENS IN PREIMMUNE SAIMIRI-SCIUREUS MONKEYS
R. Perraut et al., INDUCTION OF OPSONIZING ANTIBODIES AFTER INJECTION OF RECOMBINANT PLASMODIUM-FALCIPARUM VACCINE CANDIDATE ANTIGENS IN PREIMMUNE SAIMIRI-SCIUREUS MONKEYS, Infection and immunity, 63(2), 1995, pp. 554-562
We have previously shown that Plasmodium falciparum recombinant antige
ns PfEB200, R23, and Pfi72 inhibit opsonization of infected erythrocyt
es by hyperimmune Saimiri sera, indicating that they contain target ep
itopes involved in the phagocytosis of infected erythrocytes. We have
investigated in this study the immune response of Saimiri monkeys with
previous experience of malaria infections (preimmune monkeys) after i
njection of these recombinant antigens, administered alone or simultan
eously. The humoral response to the recombinant antigens was monitored
by radioimmunoassay, and the response to P. falciparum blood stages w
as assayed by immunofluorescence. The relative proportion of protectiv
e versus nonprotective immunoglobulin subtypes was investigated by usi
ng 3A2/G6 and 3E4/H8 monoclonal antibodies, and the capacity of the an
tisera to promote in vitro phagocytosis of infected erythrocytes was e
valuated. The antigens evoked in most cases a secondary-type antibody
response, resulting in important increases in antigen-specific antibod
y titers and concomitantly in anti-P. falciparum titers. The ratio of
3A2/G6 to 3E4/H8 immunoglobulin subtypes varied with the immunogen use
d. Opsonizing antibodies were boosted in several animals, the most pro
mising combination being the mixture of PfEB200 and R23 that induced l
ong-lasting production in five of five animals. The detectable opsoniz
ing activity appearing after immunization of the animals was antigen s
pecific, as it was lost after adsorption of the recombinant antigens.
The challenge of the animals with blood stage parasites confirmed prev
ious findings showing a correlation between the presence of detectable
opsonizing antibodies in serum and protection.